American Journal of Kidney Diseases
Volume 51, Issue 1 , Pages 131-144 , January 2008

Cellular Senescence, Cardiovascular Risk, and CKD: A Review of Established and Hypothetical Interconnections

  • George Tsirpanlis, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to George Tsirpanlis, MD, Amarysias Artemidos 34C, Marousi, 15124, Athens, Greece.

Received 25 April 2007 ,Accepted 31 July 2007.

References 

  1. Lakatta EG, Levy D. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises (Part I: Aging arteries: A “set up” for vascular disease). Circulation. 2003;107:139–146
  2. Braunwald E, Zipes DP. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. (ed 7). Philadelphia, PA: Saunders; 2005;
  3. Marin J. Age-related changes in vascular responses: A review. Mech Ageing Dev. 1995;79:71–114
  4. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998–7002
  5. Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost. 2002;28:555–568
  6. Lakatta EG. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises (Part III: Cellular and molecular clues to heart and arterial aging). Circulation. 2003;107:490–497
  7. Minamino T, Komuro I. Vascular cell senescence: Contribution to atherosclerosis. Circ Res. 2007;100:15–26
  8. Locatelli F, Bommer J, London GM, et al. Cardiovascular disease determinants in chronic renal failure: Clinical approach and treatment. Nephrol Dial Transplant. 2001;16:459–468
  9. Tsirpanlis G. The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in end-stage renal failure patients. Kidney Blood Press Res. 2005;28:55–61
  10. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?. Am J Kidney Dis. 1998;32:853–906
  11. Foley RN, Parfrey PS, Sarnak M. Epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis. 1998;32(suppl 3):S112–S119
  12. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606–1615
  13. Fuster JJ, Andres V. Telomere biology and cardiovascular disease. Circ Res. 2006;99:1167–1180
  14. Chen J, Goligorsky MS. Premature senescence of endothelial cells: Methusaleh’s dilemma. Am J Physiol Heart Circ Physiol. 2006;290:1729–1739
  15. Ben-Porath I, Weinberg RA. When cells get stressed: An integrative view of cellular senescence. J Clin Invest. 2004;113:8–13
  16. Wright WE, Shay JW. Historical claims and current interpretations of replicative aging. Nat Biotechnol. 2002;20:682–688
  17. Sherr CJ, DePinho RA. Cellular senescence: Mitotic clock or culture shock?. Cell. 2000;102:407–410
  18. Campisi J. Cancer, aging and cellular senescence. In Vivo. 2000;14:183–188
  19. Sitte N, Merker K, Von Zglinicki T, Grune T, Davies KJ. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts (I. Effects of proliferative senescence). FASEB J. 2000;14:2495–2502
  20. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113:703–716
  21. Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol. 2001;13:748–753
  22. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37:961–976
  23. Campisi J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell. 2005;120:513–522
  24. Parrinello S, Coppe J-P, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: Senescent fibroblasts alter epithelial cell differentiation. Cell Sci. 2005;118:485–496
  25. Zhang H, Pan K-H, Cohen SN. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad Sci U S A. 2003;100:3251–3256
  26. Krtolica A, Campisi J. Cancer and aging: A model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol. 2002;34:1401–1414
  27. Gire Roux P, Wynford-Thomas D, Brondello JM, Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J. 2004;23:2554–2563
  28. Kaneko T, Tahara S, Taguchi T, Kondo H. Accumulation of oxidative DNA damage, 8-oxo-2′-deoxyguanoside, and change of repair systems during in vitro cellular aging of cultured human skin fibroblasts. Mutat Res. 2001;487:19–30
  29. Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci U S A. 1994;91:4130–4134
  30. Robles SJ, Adami GR. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene. 1998;16:1113–1123
  31. Lloyd AC. Limits to lifespan. Nat Cell Biol. 2002;4:E25–E27
  32. Vousden KH, Lane DP. P53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–283
  33. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res. 1991;196:33–39
  34. Satyanarayana A, Wiemann SU, Buer J, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J. 2003;22:4003–4013
  35. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109:335–346
  36. Dimri GP, Lee X, Basile G, et al. A novel biomarker identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92:9363–9367
  37. Kuju KS, Lehman JM. Increased p53 protein associated with aging in human diploid fibroblasts. Exp Cell Res. 1995;217:336–345
  38. Dirac AM, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem. 2003;278:11731–11734
  39. Castro ME, del Valle Guijarro M, Moneo V, Carnero A. Cellular senescence induced by p-53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. J Cell Biochem. 2004;92:514–524
  40. Favetta LA, Robert C, King WA, Betts DH. Expression profiles of p53 and p66shc during oxidative stress-induced senescence in fetal bovine fibroblasts. Exp Cell Res. 2004;299:36–48
  41. Chen QM, Liu J, Merret JB. Apoptosis or senescence-like growth arrest: Influence of cell-cycle position, p53, p21 and bax in H2O2 response of normal human fibroblasts. Biochem J. 2000;347:543–551
  42. Bladier C, Volvetang EJ, Hutchinson P, de Haan JB, Kola I. Response of a primary human fibroblast cell line to H2O2: Senescence-like growth arrest or apoptosis?. Cell Growth Differ. 1997;8:589–598
  43. Rincheval V, Renaud F, Lemaire C, et al. Bcl-2 can promote p-53 dependent senescence versus apoptosis without affecting the G1/S transition. Biochem Biophys Res Commun. 2002;298:282–288
  44. Rebbaa A, Zheng X, Chou PM, Mirkin BL. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene. 2003;22:2805–2811
  45. Zhang J, Patel JM, Block ER. Enhanced apoptosis in prolonged cultures of senescent porcine pulmonary artery endothelial cells. Mech Ageing Dev. 2002;123:613–625
  46. Blackburn EH. Telomeres and telomerase: Their mechanism of action and the effects of altering their functions. FEBS Lett. 2005;579:859–862
  47. Cech TR. Beginning to understand the end of the chromosome. Cell. 2004;116:273–279
  48. Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106:661–673
  49. Blasco MA. Telomeres and human disease: Ageing, cancer and beyond. Nat Rev Genet. 2005;6:611–622
  50. McElligott R, Wellinger RJ. The terminal DNA structure of mammalian chromosomes. EMBO J. 1997;16:3705–3714
  51. Wellinger RJ, Sen D. The DNA structures at the ends of eukaryotic chromosomes. Eur J Cancer. 1997;33:735–749
  52. Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. 1997;11:2801–2809
  53. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503–514
  54. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458–460
  55. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 2002;295:2446–2449
  56. Li C-Z, Eller MS, Firoozabadi R, Gilchrest BA. Evidence that exposure of the telomere 3′ overhang sequence induces senescence. Proc Natl Acad Sci U S A. 2003;100:527–531
  57. Bodnar AG, Quellete M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349–352
  58. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol. 1998;8:279–282
  59. Zhu J, Wang H, Bishop JM, Blackburn EH. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci U S A. 1999;96:3723–3728
  60. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell. 2003;114:241–253
  61. Geserick C, Blasco MA. Novel roles for telomerase in aging. Mech Aging Dev. 2006;127:579–583
  62. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: Role of telomere in endothelial dysfunction. Circulation. 2002;105:1541–1544
  63. Vasile E, Tomita Y, Brown LF, Kocher O, Dvorak HF. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: Evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J. 2001;15:458–466
  64. Fenton M, Barker S, Kurz DJ, Erusalimsky JD. Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries. Arterioscler Thromb Vasc Biol. 2001;21:220–226
  65. Liao S, Curci JA, Kelley BJ, Sicard GA, Thompson RW. Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms compared to the adjacent inferior mesenteric artery. J Surg Res. 2000;92:85–95
  66. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res. 2005;66:286–294
  67. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:266–274
  68. Haendeler J. Nitric oxide and endothelial cell aging. Eur J Clin Pharmacol. 2006;62:137–140
  69. Dimmeler S, Zeiher AM. Nitric oxide—An endothelial cell survival factor. Cell Death Differ. 1999;6:964–968
  70. Hoffman J, Haendeler J, Aicher A, et al. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: Important role of nitric oxide. Circ Res. 2001;89:709–715
  71. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu C-P, Tsao PS. eNOS activity is reduced in senescent human endothelial cells (Preservation by hTERT immortalization). Circ Res. 2001;89:793–798
  72. Vasa M, Breitschopf K, Zeiher AM, Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res. 2000;87:540–542
  73. Hayashi T, Matsui-Hirai H, Miyazaki-Akita A, et al. Endothelial cellular senescence is inhibited by nitric oxide: Implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci USA. 2006;103:17018–17023
  74. Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci. 2004;117:2417–2426
  75. Deshpande SS, Qi B, Park YC, Irani K. Constitutive activation of rac1 results in mitochondrial oxidative stress and induces premature endothelial cell senescence. Arterioscler Thromb Vasc Biol. 2003;23:e1–e6
  76. van der Loo B, Labugger R, Skepper JN, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med. 2000;192:1731–1744
  77. Scalera F, Borlak J, Beckmann B, et al. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl l-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol. 2004;24:1816–1822
  78. Shelton DN, Chang E, Whittier PS, Choi D, Funk WD. Microarray analysis of replicative senescence. Curr Biol. 1999;9:939–945
  79. Effros RB. Telomerase induction in T cells: A cure for aging and disease?. Exp Gerontol. 2007;42:416–420
  80. Effros RT, Dagarag M, Spaulding C, Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev. 2005;205:147–157
  81. Maier JA, Statuto M, Ragnotti G. Senescence stimulates U937-endothelial cell interactions. Exp Cell Res. 1993;208:270–274
  82. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature. 1993;362:801–809
  83. Henson PM. Dampening inflammation. Nat Immunol. 2005;6:1179–1181
  84. Serhan CN, Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol. 2005;6:1191–1197
  85. Liu J, Thewke DP, Ru Su Y, Linton MRF, Fazio S, Sinensky MS. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol. 2005;25:174–179
  86. Guevara NV, Kim H-S, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999;5:335–339
  87. van Vlijmen BJM, Gerritsen G, Franken AL, et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE 3-Leiden transgenic mice. Circ Res. 2001;88:780–786
  88. Merched AJ, Williams E, Chan L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol. 2003;23:1608–1614
  89. Ogawa D, Nomiyama T, Nakamachi T, et al. Activation of peroxisome proliferator-activated receptor γ suppresses telomerase activity in vascular smooth muscle cells. Circ Res. 2006;98:e50–e59
  90. Poch E, Carbonell P, Franco S, Díez-Juan A, Blasco MA, Andrés V. Short telomeres protect from diet-induced atherosclerosis in apolipoprotein E-null mice. FASEB J. 2004;18:418–420
  91. Matthews C, Gorenne I, Scott S, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis (Effects of telomerase and oxidative stress). Circ Res. 2006;99:156–164
  92. von der Thusen JH, van Vlijmen BJM, Hoeben RC, et al. Inductions of atherosclerotic plaque rupture in apolipoprotein E−/− mice after adenovirus-mediated transfer of p53. Circulation. 2002;105:2064–2070
  93. Clarke M, Bennett M. The emerging role of vascular smooth muscle cell apoptosis in atherosclerosis and plaque stability. Am J Nephrol. 2006;26:531–535
  94. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15–26
  95. Nyunoya T, Monick MM, Klingelhutz A, Yarovinsky TO, Cagley JR, Hunninghake GW. Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol. 2006;35:681–688
  96. Chen J, Brodsky SV, Goligorsky DM, et al. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res. 2002;90:1290–1298
  97. Kunieda T, Minamino T, Nishi J, et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation. 2006;114:953–960
  98. Kunieda T, Minamino T, Katsuno T, et al. Cellular senescence impairs circadian expression of clock genes in vitro and in vivo. Circ Res. 2006;98:532–539
  99. Misiti S, Nanni S, Fontemaggi G, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol. 2000;20:3764–3771
  100. Perez-Rivero G, Ruiz-Torres MP, Rivas-Elena JV, et al. Mice deficient in telomerase activity develop hypertension because of an excess of endothelin production. Circulation. 2006;114:309–317
  101. Gardner JP, Li S, Srinivasan SR, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111:2171–2177
  102. Adaikalakoteswari A, Balasubramanyam M, Ravikumar R, Deepa R, Mohan V. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. Atherosclerosis. 2007;195:83–89
  103. Adaikalakoteswari A, Balasubramanyam M, Mohan V. Telomere shortening occurs in Asian Indian type 2 diabetic patients. Diabet Med. 2005;22:1151–1156
  104. Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care. 2006;29:283–289
  105. Aviv A, Valdes A, Gardner JP, Swaminathan R, Kimura M, Spector TD. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J Clin Endocrinol Metab. 2006;91:635–640
  106. Jeanclos E, Schork NJ, Kyvik KO, Kimura M, Skurnick JH, Aviv A. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension. 2000;36:195–200
  107. Valdes AM, Andrew T, Gardner P, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366:662–664
  108. Demissie S, Levy D, Benjamin EJ, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte length in men from the Framingham Heart Study. Aging Cell. 2006;5:325–330
  109. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004;101:17312–17315
  110. Epel ES, Lin J, Wilhelm FH, et al. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology. 2006;31:277–287
  111. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res. 2004;95:343–353
  112. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol. 2005;45:1441–1448
  113. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens. 2005;23:97–104
  114. Imanishi T, Hano T, Sawamura T, Nishio I. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp Pharmacol Physiol. 2004;31:407–410
  115. Verma S, Kuliszewski MA, Li S-H, et al. C-Reactive protein attenuates endothelial progenitor cell survival, differentiation, and function (Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease). Circulation. 2004;109:2058–2067
  116. Fujii H, Li SH, Szmitko PE, Fedak P, Verma S. C-Reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2006;26:2476–2482
  117. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens. 2005;23:1831–1837
  118. Aviv A, Valdes AM, Spector TD. Human telomere biology: Pitfalls of moving from the laboratory to epidemiology. Int J Epidemiol. 2006;35:1424–1429
  119. Nawrot TS, Staessen JA, Gardner JP, Aviv A. Telomere length and possible link to X chromosome. Lancet. 2004;363:507–510
  120. Andrew T, Aviv A, Falchi M, et al. Mapping genetic loci that determine leukocyte telomere length in a large sample of unselected, female sibling pairs. Am J Hum Genet. 2006;78:480–486
  121. Vasa-Nicotera M, Brouilette S, Mangino M, et al. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet. 2005;76:147–151
  122. Blasco MA. The epigenetic regulation of mammalian telomeres. Nat Rev Genet. 2007;8:299–309
  123. Atkinson SP, Keith WN. Epigenetic control of cellular senescence in disease: Opportunities for therapeutic intervention. Expert Rev Mol Med. 2007;9:1–26
  124. Cherkas LF, Aviv A, Valdes AM, et al. The effects of social status on biological ageing as measured by white cell telomere length. Aging Cell. 2006;5:361–367
  125. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol. 2004;39:687–699
  126. Hansson GK, Robertson A-K, Soderberg-Naucler C. Inflammation and atherosclerosis. Ann Rev Pathol Mech Dis. 2006;1:297–329
  127. Tsirpanlis G. Inflammation in atherosclerosis and other conditions: A response to danger. Kidney Blood Press Res. 2005;28:211–217
  128. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381–1478
  129. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet. 2001;358:472–473
  130. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length blood and mortality in people aged 60 years or older. Lancet. 2003;361:393–395
  131. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23:842–846
  132. Obana N, Takagi S, Kinouchi Y, et al. Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. Intern Med. 2003;42:150–153
  133. Benetos A, Gardner JP, Zureik M, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension. 2004;43:182–185
  134. Collerton J, Martin-Ruiz C, Kenny A, et al. Telomere length is associated with left ventricular function in the oldest old: The Newcastle 85+ study. Eur Heart J. 2007;28:172–176
  135. Bischoff C, Petersen HC, Graakjaer J, et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology. 2006;17:190–194
  136. Fitzpatrick AL, Kronmal RA, Gardner JP, et al. Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study. Am J Epidemiol. 2007;165:14–21
  137. Brouilette SW, Moore JS, McMahon AD, et al. Telomere length, risk of coronary disease, and statin treatment in the West of Scotland Primary Prevention Study: A nested case-control study. Lancet. 2007;369:107–114
  138. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003;92:1049–1055
  139. Spyridopoulos I, Dimmeler S. Can telomere length predict cardiovascular risk?. Lancet. 2007;369:81–82
  140. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation. 2004;110:3136–3142
  141. Haendeler J, Hoffmann J, Diehl JF, et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res. 2004;94:768–775
  142. Brodsky SV, Gealekman O, Chen J, et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res. 2004;94:377–384
  143. Bode-Boger SM, Martens-Lobenhoffer J, Tager M, Schroder H, Scalera F. Aspirin reduces endothelial cell senescence. Biochem Biophys Res Commun. 2005;334:1226–1232
  144. Scalera F, Martens-Lobenhoffer J, Tager M, Bukowska A, Lendeckel U, Bode-Boger SM. Effect of l-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial cell aging. Biochem Biophys Res Commun. 2006;245:1075–1082
  145. Doshida M, Ohmichi M, Tsutsumi S, et al. Raloxifene increases proliferation and upregulates telomerase activity in human umbilical vein endothelial cells. J Biol Chem. 2006;281:24270–24278
  146. Ramirez R, Carracedo J, Soriano S, et al. Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis. Am J Kidney Dis. 2005;45:353–359
  147. Jimenez R, Carracedo J, Santamaria R, et al. Replicative senescence in patients with chronic kidney failure. Kidney Int Suppl. 2005;99:S11–S15
  148. Boxall MC, Goodship T, Brown AL, Ward MC, von Zglinicki T. Telomere shortening and haemodialysis. Blood Purif. 2006;24:185–189
  149. Tsirpanlis G, Chatzipanagiotou S, Boufidou F, et al. Telomerase activity is decreased in peripheral blood mononuclear cells of hemodialysis patients. Am J Nephrol. 2006;26:91–96
  150. Tsirpanlis G, Chatzipanagiotou S, Boufidou F, et al. Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients. Nephrology (Carlton). 2006;11:506–509
  151. Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology (A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)). Kidney Int. 2006;70:2058–2065

PII: S0272-6386(07)01364-9

doi: 10.1053/j.ajkd.2007.07.035

American Journal of Kidney Diseases
Volume 51, Issue 1 , Pages 131-144 , January 2008

Article Tools

* Image Usage & Resolution